Bhagirathbhai Dholaria, MD
Dr. Dholaria is currently an associate professor in the Department of Hematology-Oncology at Vanderbilt University Medical Center, Nashville, TN. His areas of specialization and primary research focus are lymphoid neoplasms, plasma cell malignancies, adoptive cellular therapies, and stem cell transplantation. He has conducted studies investigating the outcomes of patients with non- Hodgkin lymphoma and acute leukemia undergoing chimeric antigen receptor T-cell (CAR-T) therapies. He is involved in translational research investigating the biomarkers of CAR T-cell therapy-associated toxicities. He has also conducted several observational studies utilizing cancer registries to study transplant outcomes of acute leukemia patients and presented his findings in national meetings. His team’s work on stem cell transplantation has been published in multiple manuscripts. His current research efforts are focused on testing novel agents to address relapse after CAR T therapy in lymphoma and multiple myeloma.
Financial relationships
-
Attribution:SelfType of financial relationship:TravelIneligible company:JanssenDate added:08/09/2023Date updated:04/04/2024Relationship end date:06/06/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ADC therapeuticsDate added:08/09/2023Date updated:04/04/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ArivanDate added:08/09/2023Date updated:04/04/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:MJH bioDate added:08/09/2023Date updated:04/04/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:PfizerDate added:08/09/2023Date updated:04/04/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BMSDate added:08/09/2023Date updated:04/04/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:GileadDate added:08/09/2023Date updated:04/04/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AngiocrineDate added:08/09/2023Date updated:04/04/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:WugenDate added:08/09/2023Date updated:04/04/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:TakedaDate added:08/09/2023Date updated:04/04/2024